Literature DB >> 22912394

The promise of patient-derived xenografts: the best laid plans of mice and men.

Scott Kopetz1, Robert Lemos, Garth Powis.   

Abstract

Compared with xenografts from previously established cell lines, patient-derived xenografts may more faithfully recapitulate the molecular diversity, cellular heterogeneity, and histology seen in patient tumors, although other limitations of murine models remain. The ability of these models to inform clinical development and answer mechanistic questions will determine their ultimate use.

Entities:  

Mesh：

Year:  2012        PMID： 22912394      PMCID： PMC4217576          DOI： 10.1158/1078-0432.CCR-12-2408

Source DB:  PubMed          Journal:  Clin Cancer Res        ISSN： 1078-0432            Impact factor:   12.531


  11 in total

1.  Finding the tumor copycat. Therapy fails, patients don't.

Authors:  Lee M Ellis; Isaiah J Fidler
Journal:  Nat Med       Date:  2010-09       Impact factor: 53.440

2.  Tumor grafts derived from women with breast cancer authentically reflect tumor pathology, growth, metastasis and disease outcomes.

Authors:  Yoko S DeRose; Guoying Wang; Yi-Chun Lin; Philip S Bernard; Saundra S Buys; Mark T W Ebbert; Rachel Factor; Cindy Matsen; Brett A Milash; Edward Nelson; Leigh Neumayer; R Lor Randall; Inge J Stijleman; Bryan E Welm; Alana L Welm
Journal:  Nat Med       Date:  2011-10-23       Impact factor: 53.440

3.  Generation of orthotopic and heterotopic human pancreatic cancer xenografts in immunodeficient mice.

Authors:  Michael P Kim; Douglas B Evans; Huamin Wang; James L Abbruzzese; Jason B Fleming; Gary E Gallick
Journal:  Nat Protoc       Date:  2009-10-29       Impact factor: 13.491

4.  A pilot clinical study of treatment guided by personalized tumorgrafts in patients with advanced cancer.

Authors:  Manuel Hidalgo; Elizabeth Bruckheimer; N V Rajeshkumar; Ignacio Garrido-Laguna; Elizabeth De Oliveira; Belen Rubio-Viqueira; Steven Strawn; Michael J Wick; James Martell; David Sidransky
Journal:  Mol Cancer Ther       Date:  2011-06-14       Impact factor: 6.261

5.  Characterization of a large panel of patient-derived tumor xenografts representing the clinical heterogeneity of human colorectal cancer.

Authors:  Sylvia Julien; Ana Merino-Trigo; Ludovic Lacroix; Marc Pocard; Diane Goéré; Pascale Mariani; Sophie Landron; Ludovic Bigot; Fariba Nemati; Peggy Dartigues; Louis-Bastien Weiswald; Denis Lantuas; Loïc Morgand; Emmanuel Pham; Patrick Gonin; Virginie Dangles-Marie; Bastien Job; Philippe Dessen; Alain Bruno; Alain Pierré; Hugues De Thé; Hany Soliman; Manoel Nunes; Guillaume Lardier; Loreley Calvet; Brigitte Demers; Grégoire Prévost; Patricia Vrignaud; Sergio Roman-Roman; Olivier Duchamp; Cyril Berthet
Journal:  Clin Cancer Res       Date:  2012-07-23       Impact factor: 12.531

Review 6.  PI-3-Kinase inhibitors in colorectal cancer.

Authors:  N T Ihle; G Powis; S Kopetz
Journal:  Curr Cancer Drug Targets       Date:  2011-02       Impact factor: 3.428

7.  Imageable fluorescent metastasis resulting in transgenic GFP mice orthotopically implanted with human-patient primary pancreatic cancer specimens.

Authors:  Atsushi Suetsugu; Matthew Katz; Jason Fleming; Mark Truty; Ryan Thomas; Shigetoyo Saji; Hisataka Moriwaki; Michael Bouvet; Robert M Hoffman
Journal:  Anticancer Res       Date:  2012-04       Impact factor: 2.480

Review 8.  The use of xenograft models for the selection of cancer treatments with the EGFR as an example.

Authors:  Teresa Troiani; Clorinda Schettino; Erika Martinelli; Floriana Morgillo; Giampaolo Tortora; Fortunato Ciardiello
Journal:  Crit Rev Oncol Hematol       Date:  2008-03       Impact factor: 6.312

9.  Anticancer drug response and expression of molecular markers in early-passage xenotransplanted colon carcinomas.

Authors:  I Fichtner; W Slisow; J Gill; M Becker; B Elbe; T Hillebrand; M Bibby
Journal:  Eur J Cancer       Date:  2004-01       Impact factor: 9.162

Review 10.  In vitro assays of chemotherapeutic sensitivity.

Authors:  D N Carney; C F Winkler
Journal:  Important Adv Oncol       Date:  1985
View more
  77 in total

Review 1.  Patient-Derived Xenograft Models in Breast Cancer Research.

Authors:  Deukchae Na; Hyeong-Gon Moon
Journal:  Adv Exp Med Biol       Date:  2021       Impact factor: 2.622

Review 2.  The chick chorioallantoic membrane (CAM) as a versatile patient-derived xenograft (PDX) platform for precision medicine and preclinical research.

Authors:  Logan C DeBord; Ravi R Pathak; Mariana Villaneuva; Hsuan-Chen Liu; Daniel A Harrington; Wendong Yu; Michael T Lewis; Andrew G Sikora
Journal:  Am J Cancer Res       Date:  2018-08-01       Impact factor: 6.166

3.  Patient-derived Xenografts from Colorectal Carcinoma: A Temporal and Hierarchical Study of Murine Stromal Cell Replacement.

Authors:  Celia Chao; Steve G Widen; Thomas G Wood; John R Zatarain; Paul Johnson; Aakash Gajjar; Guillermo Gomez; Suimin Qiu; Jill Thompson; Heidi Spratt; Mark R Hellmich
Journal:  Anticancer Res       Date:  2017-07       Impact factor: 2.480

4.  Integrated next-generation sequencing and avatar mouse models for personalized cancer treatment.

Authors:  Elena Garralda; Keren Paz; Pedro P López-Casas; Siân Jones; Amanda Katz; Lisa M Kann; Fernando López-Rios; Francesca Sarno; Fátima Al-Shahrour; David Vasquez; Elizabeth Bruckheimer; Samuel V Angiuoli; Antonio Calles; Luis A Diaz; Victor E Velculescu; Alfonso Valencia; David Sidransky; Manuel Hidalgo
Journal:  Clin Cancer Res       Date:  2014-03-14       Impact factor: 12.531

5.  Unstable Genome and Transcriptome Dynamics during Tumor Metastasis Contribute to Therapeutic Heterogeneity in Colorectal Cancers.

Authors:  Sung-Yup Cho; Jeesoo Chae; Deukchae Na; Wonyoung Kang; Ahra Lee; Seoyeon Min; Jinjoo Kang; Boram Choi; Jieun Lee; Chang Ohk Sung; Jeffrey H Chuang; Charles Lee; Won-Suk Lee; Hansoo Park; Jong-Il Kim
Journal:  Clin Cancer Res       Date:  2019-01-22       Impact factor: 12.531

6.  Preclinical models for interrogating drug action in human cancers using Stable Isotope Resolved Metabolomics (SIRM).

Authors:  Andrew N Lane; Richard M Higashi; Teresa W-M Fan
Journal:  Metabolomics       Date:  2016-06-29       Impact factor: 4.290

7.  Development and characterization of a colon PDX model that reproduces drug responsiveness and the mutation profiles of its original tumor.

Authors:  Hyang Sook Seol; Hyo Jeong Kang; Hyojeong Kang; Seul-I Lee; Na Eun Kim; Tae Im Kim; Sung Min Chun; Tae Won Kim; Chang Sik Yu; Young-Ah Suh; Shree Ram Singh; Suhwan Chang; Se Jin Jang
Journal:  Cancer Lett       Date:  2013-12-11       Impact factor: 8.679

8.  Combined BRAF and MEK Inhibition With Dabrafenib and Trametinib in BRAF V600-Mutant Colorectal Cancer.

Authors:  Ryan B Corcoran; Chloe E Atreya; Gerald S Falchook; Eunice L Kwak; David P Ryan; Johanna C Bendell; Omid Hamid; Wells A Messersmith; Adil Daud; Razelle Kurzrock; Mariaelena Pierobon; Peng Sun; Elizabeth Cunningham; Shonda Little; Keith Orford; Monica Motwani; Yuchen Bai; Kiran Patel; Alan P Venook; Scott Kopetz
Journal:  J Clin Oncol       Date:  2015-09-21       Impact factor: 44.544

Review 9.  Development and Significance of Mouse Models in Lymphoma Research.

Authors:  Jordan N Noble; Anjali Mishra
Journal:  Curr Hematol Malig Rep       Date:  2019-04       Impact factor: 3.952

10.  A novel patient-derived xenograft model for claudin-low triple-negative breast cancer.

Authors:  Margarite D Matossian; Hope E Burks; Annie C Bowles; Steven Elliott; Van T Hoang; Rachel A Sabol; Nicholas C Pashos; Benjamen O'Donnell; Kristin S Miller; Bahia M Wahba; Bruce A Bunnell; Krzysztof Moroz; Arnold H Zea; Steven D Jones; Augusto C Ochoa; Amir A Al-Khami; Fokhrul Hossain; Adam I Riker; Lyndsay V Rhodes; Elizabeth C Martin; Lucio Miele; Matthew E Burow; Bridgette M Collins-Burow
Journal:  Breast Cancer Res Treat       Date:  2018-02-01       Impact factor: 4.872
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.